• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡西瑞维单抗/英地维单抗与瑞德西韦联合治疗B细胞耗竭患者的持续性SARS-CoV-2感染

Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients.

作者信息

Dioverti M Veronica, Gaston David C, Morris C Paul, Huff Carol Ann, Jain Tania, Jones Richard, Anders Viki, Lederman Howard, Saunders Jacqueline, Mostafa Heba H, Avery Robin K

机构信息

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Division of Medical Microbiology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.

出版信息

Open Forum Infect Dis. 2022 May 26;9(6):ofac064. doi: 10.1093/ofid/ofac064. eCollection 2022 Jun.

DOI:10.1093/ofid/ofac064
PMID:35663288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9154336/
Abstract

Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present 3 B-cell-depleted patients with prolonged coronavirus disease 2019 infection who were successfully treated with a combination of casirivimab/imdevimab and remdesivir.

摘要

由于无法产生足够的体液免疫反应来清除病毒,B细胞严重耗竭的患者可能会出现严重急性呼吸综合征冠状病毒2的长期感染并有病毒活跃复制的证据。我们报告了3例B细胞耗竭的2019冠状病毒病长期感染患者,他们接受了卡西瑞维单抗/伊德维单抗和瑞德西韦联合治疗并取得成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bf/9154336/f8ef17c2e3f7/ofac064_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bf/9154336/f8ef17c2e3f7/ofac064_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bf/9154336/f8ef17c2e3f7/ofac064_fig1.jpg

相似文献

1
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients.卡西瑞维单抗/英地维单抗与瑞德西韦联合治疗B细胞耗竭患者的持续性SARS-CoV-2感染
Open Forum Infect Dis. 2022 May 26;9(6):ofac064. doi: 10.1093/ofid/ofac064. eCollection 2022 Jun.
2
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies.利妥昔单抗治疗肾病综合征患者持续性 SARS-CoV-2 感染:瑞德西韦和单克隆抗体联合治疗成功。
Intern Med. 2022 Dec 15;61(24):3703-3708. doi: 10.2169/internalmedicine.0241-22. Epub 2022 Sep 28.
3
Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies.卡西瑞维单抗-英夫西单抗对严重急性呼吸综合征冠状病毒2德尔塔变异株鼻咽病毒载量和刺突基因准种的影响。
Open Forum Infect Dis. 2022 Feb 21;9(4):ofac093. doi: 10.1093/ofid/ofac093. eCollection 2022 Apr.
4
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience.卡西瑞维单抗/英夫利昔单抗联合瑞德西韦治疗重度新冠肺炎住院患者:单中心经验
Heliyon. 2023 Feb;9(2):e13126. doi: 10.1016/j.heliyon.2023.e13126. Epub 2023 Jan 21.
5
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.抑制德尔塔浪潮:巴姆洛单抗-埃特司韦单抗、卡司瑞韦单抗-伊德韦单抗或索特罗韦单抗治疗轻度至中度 2019 冠状病毒病的临床结局。
Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.
6
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者(RECOVERY):一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
7
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.卡司瑞韦单抗-伊德韦单抗抗体联合治疗 COVID-19 德尔塔变异株患者的临床疗效。
J Infect Chemother. 2022 Sep;28(9):1344-1346. doi: 10.1016/j.jiac.2022.05.012. Epub 2022 May 26.
8
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染:使用 casirivimab 和 imdevimab(REGN-COV2)单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
9
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.司鲁利单抗和度伐利尤单抗联合治疗 COVID-19 抗体在门诊 SARS-CoV-2 感染患者中的病毒学疗效:一项 2 期剂量范围随机临床试验。
JAMA Netw Open. 2022 Aug 1;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411.
10
Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.早期给予严重急性呼吸综合征冠状病毒2单克隆抗体可降低感染新型冠状病毒肺炎的血液系统恶性肿瘤和造血细胞移植患者的死亡风险。
Transpl Infect Dis. 2023 Feb;25(1):e14006. doi: 10.1111/tid.14006. Epub 2023 Jan 27.

引用本文的文献

1
Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.早期干预以及单克隆抗体与抗病毒药物联合治疗对感染SARS-CoV-2的肿瘤血液学患者的有效性:一项回顾性研究经验
Front Immunol. 2025 Mar 28;16:1524525. doi: 10.3389/fimmu.2025.1524525. eCollection 2025.
2
B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience.持续感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的B细胞耗竭患者:联合治疗还是单药治疗?一项真实世界经验
Front Med (Lausanne). 2024 Feb 29;11:1344267. doi: 10.3389/fmed.2024.1344267. eCollection 2024.
3

本文引用的文献

1
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.利妥昔单抗治疗后 B 细胞耗竭患者的 COVID-19:诊断和治疗挑战。
Front Immunol. 2021 Nov 3;12:763412. doi: 10.3389/fimmu.2021.763412. eCollection 2021.
2
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.接受CD20靶向免疫化疗的B细胞淋巴瘤患者中的新型冠状病毒肺炎
Hemasphere. 2021 Jun 28;5(7):e603. doi: 10.1097/HS9.0000000000000603. eCollection 2021 Jul.
3
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?
慢性淋巴细胞白血病患者中的新冠病毒肺炎:我们了解到了什么?
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
4
Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan.日本爱知县单中心回顾性研究:瑞德西韦联合单克隆抗体与瑞德西韦单药治疗轻中度 COVID-19 合并免疫抑制患者的比较有效性和安全性的真实世界经验。
Viruses. 2023 Sep 19;15(9):1952. doi: 10.3390/v15091952.
5
Remdesivir Use in the Real-World Setting: An Overview of Available Evidence.瑞德西韦在真实世界环境中的应用:现有证据概述。
Viruses. 2023 May 14;15(5):1167. doi: 10.3390/v15051167.
6
COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.血液系统恶性肿瘤成年患者中的COVID-19——大流行三年后的经验教训
Biology (Basel). 2023 Apr 3;12(4):545. doi: 10.3390/biology12040545.
7
Respiratory Adenovirus Quantification with a Droplet Digital Polymerase Chain Reaction (ddPCR) Assay.采用液滴式数字聚合酶链反应(ddPCR)检测法定量呼吸道腺病毒。
Microbiol Spectr. 2023 Jun 15;11(3):e0026923. doi: 10.1128/spectrum.00269-23. Epub 2023 Apr 18.
8
Case report: Clinical course and treatment of SARS-CoV-2 in a pediatric CAR-T cell recipient with persistent hypogammaglobulinemia.病例报告:一名患有持续性低丙种球蛋白血症的儿科CAR-T细胞接受者感染新型冠状病毒2的临床病程及治疗情况
Front Pediatr. 2023 Mar 10;11:1076686. doi: 10.3389/fped.2023.1076686. eCollection 2023.
9
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.免疫功能低下患者中持续的SARS-CoV-2感染促进病毒快速进化:回顾性队列研究与文献综述
Clin Infect Pract. 2022 Nov;16:100210. doi: 10.1016/j.clinpr.2022.100210. Epub 2022 Nov 16.
10
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study.卡拉布里亚地区一个地区服务中心的冠状病毒病早期治疗的经验教训和影响:一项回顾性研究。
BMC Infect Dis. 2022 Oct 20;22(1):793. doi: 10.1186/s12879-022-07774-9.
单克隆抗体组合药物 REGEN-COV 可预防 SARS-CoV-2 突变逃逸,这一结论在临床前和人体研究中得到验证。
Cell. 2021 Jul 22;184(15):3949-3961.e11. doi: 10.1016/j.cell.2021.06.002. Epub 2021 Jun 5.
4
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.接受B细胞耗竭疗法的患者和体液免疫缺陷状态患者的COVID-19结局:一项范围综述
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
5
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach.使用B细胞耗竭药物的患者中严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染的长期及成功治疗:一种定制化方法
Int J Infect Dis. 2021 Jun;107:247-250. doi: 10.1016/j.ijid.2021.04.068. Epub 2021 Apr 24.
6
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.SARS-CoV-2 变异株 P.1 对抗体中和的抵抗力增强。
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. doi: 10.1016/j.chom.2021.04.007. Epub 2021 Apr 18.
7
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
8
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2,一种中和抗体鸡尾酒疗法,用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
9
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer.癌症免疫抑制治疗后活的严重急性呼吸综合征冠状病毒2的脱落
N Engl J Med. 2020 Dec 24;383(26):2586-2588. doi: 10.1056/NEJMc2031670. Epub 2020 Dec 1.
10
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.